This study is for men aged 12 to 74 with severe hemophilia A (a rare bleeding disorder where blood doesn't clot normally) who are currently taking emicizumab. The purpose is to understand the safety of switching from emicizumab to a new medicine called marstacimab. Researchers will look for any side effects (adverse events) that happen while taking marstacimab. You would be eligible if you have severe hemophilia A (FVIII activity <1%) without inhibitors (antibodies that can make treatments less effective) and have been on emicizumab for at least 6 months. The study is currently unclear about its recruitment status and plans to enroll about 15 participants.

Study design

This is an open-label study, meaning you and your doctors will know which treatment you are receiving. It is not randomized, and about 10-15 participants will be included.

What's involved

You would take marstacimab once weekly by injection under the skin for about 4 months, after a 14-day break from emicizumab. The total study duration for each participant is about 6 months.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored for at least 28 days after your last dose of marstacimab.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.